{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:26:35Z","timestamp":1786987595307,"version":"build-2736575974"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012306","name":"Universit\u00e0 degli Studi di Trieste","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007406","name":"Fundaci\u00f3n BBVA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007406","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ctrv.2022.102468","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T11:59:42Z","timestamp":1664366382000},"page":"102468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer"],"prefix":"10.1016","volume":"111","author":[{"given":"Francesco","family":"Schettini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Venturini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Pinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta Elisa","family":"Onesti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"De Placido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Harbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"L\u00fcftner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannelore","family":"Denys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Van Dam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Arpino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Mustacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Gligorov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Awada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Campone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Wildiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Gennari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivianne","family":"Tjan-Heijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert","family":"Bartsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabino","family":"De Placido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Del Mastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Jerusalem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleix","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Generali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2022.102468_b0005","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","article-title":"A randomised phase III trial of carboplatin compared with docetaxel in BRCA1\/2 mutated and pre-specified triple negative breast cancer \u201cBRCAness\u201d subgroups: the TNT Trial","volume":"24","author":"Tutt","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2022.102468_b0010","doi-asserted-by":"crossref","first-page":"45411","DOI":"10.1038\/srep45411","article-title":"Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study","volume":"7","author":"Gong","year":"2017","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.ctrv.2022.102468_b0015","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1002\/cncr.26576","article-title":"Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer","volume":"118","author":"Hartman","year":"2012","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102468_b0020","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102468_b0025","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2022.102468_b0030","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1200\/JCO.2020.38.15_suppl.1000","article-title":"KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer","volume":"38","author":"Cortes","year":"2020","journal-title":"JCO"},{"issue":"22","key":"10.1016\/j.ctrv.2022.102468_b0035","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102468_b0040","doi-asserted-by":"crossref","first-page":"e001558","DOI":"10.1136\/jitc-2020-001558","article-title":"Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers","volume":"8","author":"Rozenblit","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2022.102468_b0045","doi-asserted-by":"crossref","unstructured":"Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2014;2:361\u201370. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0127.","DOI":"10.1158\/2326-6066.CIR-13-0127"},{"key":"10.1016\/j.ctrv.2022.102468_b0050","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines for Breast Cancer, vers.4.2022 n.d. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf (accessed June 28, 2022)."},{"issue":"12","key":"10.1016\/j.ctrv.2022.102468_b0055","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102468_b0060","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ctrv.2022.102468_b0065","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102468_b0070","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini","year":"2021","journal-title":"npj Breast Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102468_b0075","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2022.102468_b0080","doi-asserted-by":"crossref","unstructured":"Egger SJ, Chan MMK, Luo Q, Wilcken N. Platinum-containing regimens for triple-negative metastatic breast cancer. Cochrane Database Syst Rev 2020;10:CD013750. https:\/\/doi.org\/10.1002\/14651858.CD013750.","DOI":"10.1002\/14651858.CD013750"},{"issue":"35","key":"10.1016\/j.ctrv.2022.102468_b0085","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1200\/JCO.21.01374","article-title":"Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2\u2013Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor\u2013Negative: ASCO Guideline Update","volume":"39","author":"Moy","year":"2021","journal-title":"JCO"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102468_b0090","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1","volume":"14","author":"Jansen","year":"2011","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102468_b0095","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","article-title":"Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2","volume":"14","author":"Hoaglin","year":"2011","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102468_b0100","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S1470-2045(19)30420-6","article-title":"Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis","volume":"20","author":"Giuliano","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2022.102468_b0105","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.clbc.2017.07.015","article-title":"Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials","volume":"18","author":"Li","year":"2018","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102468_b0110","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10549-015-3453-9","article-title":"A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer","volume":"152","author":"Generali","year":"2015","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102468_b0115","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S1470-2045(20)30447-2","article-title":"Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Di\u00e9ras","year":"2020","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102468_b0120","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann Oncol"},{"issue":"10265","key":"10.1016\/j.ctrv.2022.102468_b0125","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102468_b0130","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","article-title":"Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial","volume":"22","author":"Winer","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102468_b0135","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S1470-2045(17)30450-3","article-title":"Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"18","author":"Kim","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2022.102468_b0140","doi-asserted-by":"crossref","unstructured":"Dent R, Kim S-B, Oliveira M, Barrios C, O\u2019Shaughnessy J, Isakoff SJ, et al. Abstract GS3-04: Double-blind placebo (PBO)-controlled randomized phase III trial evaluating first-line ipatasertib (IPAT) combined with paclitaxel (PAC) for PIK3CA\/AKT1\/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC): primary results from IPATunity130 Cohort A. Cancer Res 2021;81:GS3-04. https:\/\/doi.org\/10.1158\/1538-7445.SABCS20-GS3-04.","DOI":"10.1158\/1538-7445.SABCS20-GS3-04"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102468_b0145","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.19.00368","article-title":"Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial","volume":"38","author":"Schmid","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102468_b0150","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10549-016-4033-3","article-title":"A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study","volume":"161","author":"Harbeck","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"10.1016\/j.ctrv.2022.102468_b0155","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S1470-2045(14)70439-5","volume":"15","author":"von Minckwitz","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102468_b0160","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S1470-2045(15)00411-8","article-title":"Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial","volume":"17","author":"Takashima","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2022.102468_b0165","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1023\/A:1008929526011","article-title":"WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibility","volume":"10","author":"Lunn","year":"2000","journal-title":"Statist Comput"},{"key":"10.1016\/j.ctrv.2022.102468_b0170","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13643-017-0473-z","article-title":"Approaches to interpreting and choosing the best treatments in network meta-analyses","volume":"6","author":"Mbuagbaw","year":"2017","journal-title":"Syst Rev"},{"key":"10.1016\/j.ctrv.2022.102468_b0175","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1214\/ss\/1177011136","article-title":"Inference from iterative simulation using multiple sequences","volume":"7","author":"Gelman","year":"1992","journal-title":"Statist Sci"},{"key":"10.1016\/j.ctrv.2022.102468_b0180","series-title":"Introduction to Applied Bayesian Statistics and Estimation for Social Scientists","first-page":"1","article-title":"Introduction to Applied Bayesian Statistics and Estimation for Social Scientists","author":"Lynch","year":"2007"},{"key":"10.1016\/j.ctrv.2022.102468_b0185","doi-asserted-by":"crossref","unstructured":"Dias S, Ades A, Welton N, Jansen J, Sutton A. Network Meta-Analysis for Decision-Making | Wiley. 1st Edition. John Wiley and Sons; 2018.","DOI":"10.1002\/9781118951651"},{"issue":"11","key":"10.1016\/j.ctrv.2022.102468_b0190","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ctrv.2022.102468_b0195","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.ctrv.2022.102468_b0200","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"key":"10.1016\/j.ctrv.2022.102468_b0205","unstructured":"R Core Team (2021). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https:\/\/www.R-project.org\/. n.d."},{"key":"10.1016\/j.ctrv.2022.102468_b0210","unstructured":"Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; n.d."},{"issue":"8","key":"10.1016\/j.ctrv.2022.102468_b0215","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2022.102468_b0220","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1093\/annonc\/mdw260","article-title":"Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study","volume":"27","author":"Delaloge","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2022.102468_b0225","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.21873\/anticanres.11462","article-title":"First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study","volume":"37","author":"Dieras","year":"2017","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102468_b0230","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/annonc\/mdq430","article-title":"First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients","volume":"22","author":"Smith","year":"2011","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102468_b0235","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ctrv.2014.01.003","article-title":"Efficacy of biological agents in metastatic triple-negative breast cancer","volume":"40","author":"Bramati","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2022.102468_b0240","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1093\/annonc\/mdt276","article-title":"First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients","volume":"24","author":"Miles","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2022.102468_b0245","doi-asserted-by":"crossref","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","article-title":"2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients","volume":"27","author":"Roila","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2022.102468_b0250","doi-asserted-by":"crossref","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO Clinical Practice Guidelines \u2020","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2022.102468_b0255","doi-asserted-by":"crossref","first-page":"iv96","DOI":"10.1093\/annonc\/mdx758","article-title":"Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines","volume":"29","author":"Aapro","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2022.102468_b0260","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.686776","article-title":"Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial","volume":"11","author":"Schettini","year":"2021","journal-title":"Front Oncol"},{"issue":"36","key":"10.1016\/j.ctrv.2022.102468_b0265","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1200\/JCO.20.02151","article-title":"TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102468_b0270","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.annonc.2020.10.471","article-title":"Neoadjuvant paclitaxel\/olaparib in comparison to paclitaxel\/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)","volume":"32","author":"Fasching","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2022.102468_b0275","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejca.2021.02.035","article-title":"Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis","volume":"149","author":"Schettini","year":"2021","journal-title":"Eur J Cancer"},{"issue":"25","key":"10.1016\/j.ctrv.2022.102468_b0280","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2022.102468_b0285","doi-asserted-by":"crossref","unstructured":"Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, K\u00fcmmel S, et al. VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC. Annals of Oncology 2021;0. https:\/\/doi.org\/10.1016\/j.annonc.2021.06.014.","DOI":"10.1016\/j.annonc.2021.06.014"},{"key":"10.1016\/j.ctrv.2022.102468_b0290","unstructured":"Roche Group Media Relations. Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer. Roche Media Releases n.d. https:\/\/www.roche.com\/media\/releases\/med-cor-2021-08-27.htm (accessed October 18, 2021)."},{"key":"10.1016\/j.ctrv.2022.102468_b0295","doi-asserted-by":"crossref","unstructured":"Rugo H, Llombart-Cussac A, Andre F, Robson ME, Saji S, Harbeck N, et al. Abstract OT-30-01: KEYLYNK-009: A phase 2\/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or m\u2026. Cancer Research 2021;81:OT-30-01-OT-30-01. https:\/\/doi.org\/10.1158\/1538-7445.SABCS20-OT-30-01.","DOI":"10.1158\/1538-7445.SABCS20-OT-30-01"},{"issue":"14","key":"10.1016\/j.ctrv.2022.102468_b0300","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.3390\/ijms20143390","article-title":"Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors","volume":"20","author":"Garutti","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2022.102468_b0305","doi-asserted-by":"crossref","first-page":"TPS1109","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS1109","article-title":"A phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer (CAPItello290)","volume":"38","author":"Schmid","year":"2020","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2022.102468_b0310","unstructured":"Therapeutics G. G1 Therapeutics Announces Initiation of Phase 3 Registrational Study of COSELATM (trilaciclib) in Triple-Negative Breast Cancer (TNBC). GlobeNewswire News Room 2021. https:\/\/www.globenewswire.com\/news-release\/2021\/04\/28\/2218475\/0\/en\/G1-Therapeutics-Announces-Initiation-of-Phase-3-Registrational-Study-of-COSELA-trilaciclib-in-Triple-Negative-Breast-Cancer-TNBC.html (accessed June 2, 2021)."},{"key":"10.1016\/j.ctrv.2022.102468_b0315","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ctrv.2016.09.004","article-title":"Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives","volume":"50","author":"Schettini","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2022.102468_b0320","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ctrv.2015.11.012","article-title":"Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review","volume":"43","author":"Puglisi","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102468_b0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102468_b0330","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102468_b0335","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical Tools for Network Meta-Analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS ONE"},{"issue":"35","key":"10.1016\/j.ctrv.2022.102468_b0340","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1200\/JCO.21.01392","article-title":"Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update","volume":"39","author":"Burstein","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102468_b0345","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1056\/NEJM199708213370810","article-title":"The promise and problems of meta-analysis","volume":"337","author":"Bailar","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2022.102468_b0350","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/oxfordjournals.aje.a117326","article-title":"Can meta-analysis be salvaged?","volume":"140","author":"Greenland","year":"1994","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ctrv.2022.102468_b0355","unstructured":"Chaimani A, Caldwell D, Li T, Higgins J, Salanti G. Chapter 11: Undertaking network meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org\/handbook. n.d."},{"key":"10.1016\/j.ctrv.2022.102468_b0360","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"issue":"17","key":"10.1016\/j.ctrv.2022.102468_b0365","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.3390\/cancers13174421","article-title":"Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer","volume":"13","author":"Schettini","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222001372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222001372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:27:17Z","timestamp":1759656437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737222001372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":73,"alternative-id":["S0305737222001372"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102468","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102468","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102468"}}